Harrow (HROW) is partnering with a subsidiary of privately held Nordic Group for the launch of an authorized generic of Maxitrol ophthalmic suspension to treat bacterial eye infections.
Financial terms of the partnership were not disclosed.
Harrow has sold Maxitrol in the US since obtaining commercial rights to the combination of neomycin and polymyxin B sulfate and dexamethasone from Novartis (NVS) in December 2021.
Maxitrol and generic equivalents had annual sales of $20.8 million in the US, according to IQVIA data, as of January.
Harrow shares recently were trading about 1.3% higher on Thursday.
Price: 24.15, Change: +0.32, Percent Change: +1.34
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。